東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Clinical Trial Data Science to Advance Precision Oncology.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Clinical Trial Data Science to Advance Precision Oncology./
作者:	Plana, Deborah.
面頁冊數:	1 online resource (196 pages)
附註:	Source: Dissertations Abstracts International, Volume: 83-12, Section: B.
Contained By:	Dissertations Abstracts International83-12B.
標題:	Bioengineering. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29061579click for full text (PQDT)
ISBN:	9798819379684

Clinical Trial Data Science to Advance Precision Oncology.
Plana, Deborah.

Clinical Trial Data Science to Advance Precision Oncology. - 1 online resource (196 pages)

Source: Dissertations Abstracts International, Volume: 83-12, Section: B.

Thesis (Ph.D.)--Harvard University, 2022.

Includes bibliographical references

Clinical trials are the most expensive and highest-stakes experiments in biomedicine, and their results determine which therapies are ultimately used to treat patients. While a typical pivotal trial costs millions of dollars and enrolls hundreds of patients, its associated data will not be made public, limiting our ability to learn from its results. We reconstructed otherwise siloed clinical trial data by using image analysis on published trial figures. We then developed methods to re-analyze these results at scale and help design more effective clinical and preclinical studies. In Chapter 1, we describe how a probabilistic model can predict the success of combination therapies in oncology using single agent data alone and how this insight can be leveraged to improve survival outcomes in presently incurable cancers. In Chapter 2, we find that a parametric distribution accurately describes the shape of survival curves in oncology trials, and we show how historical results can inform distribution parameters to more precisely infer drug efficacy from small sample sizes. We also find that differences in curve shape correspond to a violation of the proportional hazards assumption typically used to assess trial results and, consequently, that a trial's length has an underappreciated impact on its likelihood of success. In Chapter 3, we develop a more powerful approach to detect patient subgroups responding to new therapies as compared to standard methods used in oncology basket trials. Finally, in Chapter 4, we apply the lessons learned from clinical data to incorporate interpatient heterogeneity into drug and biomarker discovery efforts using patient-derived mouse xenografts. This body of work offers new tools to better understand drug-response data in human, animal, and cell line studies. We hope that these methods help take clinical findings from the bedside back to the bench and advance precision oncology.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798819379684Subjects--Topical Terms:

657580
Bioengineering.
Subjects--Index Terms:

Clinical trialsIndex Terms--Genre/Form:

542853
Electronic books.

Clinical Trial Data Science to Advance Precision Oncology.
LDR:03313nmm a2200409K 4500 001 2359732
005 20230917195229.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798819379684
035 $a (MiAaPQ)AAI29061579
035 $a AAI29061579
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Plana, Deborah. $3 3700352
245 1 0 $a Clinical Trial Data Science to Advance Precision Oncology.
264 0 $c 2022
300 $a 1 online resource (196 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 83-12, Section: B.
500 $a Advisor: Sorger, Peter K.; Palmer, Adam C.
502 $a Thesis (Ph.D.)--Harvard University, 2022.
504 $a Includes bibliographical references
520 $a Clinical trials are the most expensive and highest-stakes experiments in biomedicine, and their results determine which therapies are ultimately used to treat patients. While a typical pivotal trial costs millions of dollars and enrolls hundreds of patients, its associated data will not be made public, limiting our ability to learn from its results. We reconstructed otherwise siloed clinical trial data by using image analysis on published trial figures. We then developed methods to re-analyze these results at scale and help design more effective clinical and preclinical studies. In Chapter 1, we describe how a probabilistic model can predict the success of combination therapies in oncology using single agent data alone and how this insight can be leveraged to improve survival outcomes in presently incurable cancers. In Chapter 2, we find that a parametric distribution accurately describes the shape of survival curves in oncology trials, and we show how historical results can inform distribution parameters to more precisely infer drug efficacy from small sample sizes. We also find that differences in curve shape correspond to a violation of the proportional hazards assumption typically used to assess trial results and, consequently, that a trial's length has an underappreciated impact on its likelihood of success. In Chapter 3, we develop a more powerful approach to detect patient subgroups responding to new therapies as compared to standard methods used in oncology basket trials. Finally, in Chapter 4, we apply the lessons learned from clinical data to incorporate interpatient heterogeneity into drug and biomarker discovery efforts using patient-derived mouse xenografts. This body of work offers new tools to better understand drug-response data in human, animal, and cell line studies. We hope that these methods help take clinical findings from the bedside back to the bench and advance precision oncology.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Bioengineering. $3 657580
650 4 $a Bioinformatics. $3 553671
650 4 $a Biostatistics. $3 1002712
650 4 $a Pharmacology. $3 634543
650 4 $a Oncology. $3 751006
653 $a Clinical trials
653 $a Data science
653 $a Drug development
653 $a Precision medicine
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0202
690 $a 0715
690 $a 0308
690 $a 0992
690 $a 0419
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Harvard University. $b Systems Biology. $3 2096528
773 0 $t Dissertations Abstracts International $g 83-12B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29061579 $z click for full text (PQDT)